Suffering from obesity?..a “famous medicine” that has a magic effect

0
38


On Friday, the US Food and Drug Administration approved the use of the famous diabetes drug to treat obesity, in a step that may help many people avoid diseases caused by obesity.

And the British newspaper “Daily Mail” reported, on Saturday, that the Wegovy drug will be given to those wishing to lose weight, especially as they are a compound version of the gut hormone that curbs appetite.

The drug is injected weekly under the skin, and the drug is currently being used to treat type 2 diabetes.

Experts said the drug’s effectiveness also depends on following a healthy diet and continuing to exercise, with more than 100 million American adults suffering from obesity.

Obesity is known as a risk factor for chronic health conditions including type 2 diabetes, strokes, heart attacks and even certain types of cancer.

A study conducted to determine the effectiveness of the treatment concluded that people who received the treatment lost about 15 percent of their weight, which is equivalent to 34 pounds, over 16 months, while another group that received a placebo treatment lost about 2.5 percent of their weight.

The medical director of the “Louisville” Center for Research on Metabolism and Atherosclerosis, Harold Bayes, said that current drugs may help to lose between 5-10 percent, and sometimes not up to that.

Bayes helped conduct other studies on Wegovy’s treatment for other diabetes and obesity.

");
//},3000);
}
});
//$(window).bind('scroll');
$(window).scroll(function () {
if (alreadyLoaded_facebookConnect == false) {
alreadyLoaded_facebookConnect = true;
// $(window).unbind('scroll');
// console.log(" scroll loaded");

(function (d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.async = true;
js._https = true;
js.src = "https://connect.facebook.net/en_US/all.js#xfbml=1&appId=148379388602322";
fjs.parentNode.insertBefore(js, fjs);
}(document, 'script', 'facebook-jssdk'));
// pre_loader();
// $(window).unbind('mousemove');
//setTimeout(function(){
// $('#boxTwitter').html("");
//},3000);

var scriptTag = document.createElement("script");
scriptTag.type = "text/javascript"
scriptTag.src = "https://news.google.com/scripts/social.js";
scriptTag.async = true;
document.getElementsByTagName("head")[0].appendChild(scriptTag);

(function () {
$.getScript("https://news.google.com/scripts/social.js", function () { });
});

}
});

//$(window).load(function () {
// setTimeout(function(){
// // add the returned content to a newly created script tag
// var se = document.createElement('script');
// se.type = "text/javascript";
// //se.async = true;
// se.text = "setTimeout(function(){ pre_loader(); },5000); ";
// document.getElementsByTagName('body')[0].appendChild(se);
// },5000);
//});





LEAVE A REPLY

Please enter your comment!
Please enter your name here